Immatics

The Immatics team was back in Barcelona, this time for PEGS Europe 2024! While onsite, the team presented Immatics’ work in the field and attended sessions on cutting-edge research in immunotherapy, bispecifics, machine learning and more. Here are their top takeaways from the conference: 💡Artificial intelligence, machine learning and in silico design are making significant strides in biologics discovery, supporting advancements in multi-target and TCR-based therapeutic approaches. 💡Bispecific T cell engagers are being refined to enhance efficacy and safety, with tailored mechanisms of action at the forefront. 💡In binder discovery, high-throughput screening (deep screening) is gaining traction over classic panning, accelerating therapeutic innovations. Thank you, PEGS Europe, for another great conference! #PEGSEurope #artificialintelligence #immunotherapy #oncology #conference

In case you missed it: Last week, the Immatics team was onsite in Houston, Texas, for the 39th Annual Society for Immunotherapy of Cancer (SITC) conference, where two oral presentations and multiple posters on our clinical and preclinical-stage candidates were presented. The conference was also a great opportunity for our Tübingen and Munich colleagues to connect with the Houston team. Thank you, SITC, for another outstanding and informative conference! Interested in the data? Read the full press release here: https://lnkd.in/dHUurcEv #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews #SITC

What is a cell? What turns a “good” cell into a “bad” cell? And how can “good” cells be harnessed to treat diseases? 🎙️In this episode of the Life Sci Fantastic podcast, host, Eliot Forster, sits down with Immatics CEO, Harpreet Singh, to explore the fundamentals of cell biology and immunology, shedding light on how understanding these basic building blocks has led to innovative new cancer treatments, such as Immatics’ TCR-T cell based therapies. Listen to the full episode on your preferred podcast platform or via the following link: https://lnkd.in/dRAt9Wjx #LifeSciences #CancerResearch #Immunotherapy #CellTherapy #InnovationInMedicine #GeneTherapy #Healthcare

While onsite at the Society for Immunotherapy of Cancer (SITC) conference, Immatics CEO, Harpreet Singh, was interviewed by Brad Loncar from BiotechTV. 🎥Watch the full video for details on the recently announced data, Immatics’ cell therapy and bispecific candidates and the potential of these novel therapies to address a wide range of solid tumor cancers: https://lnkd.in/gs-Dk4FC #biotech #interview #conference #oncology #cancer #SITC #cancerresearch #innovation

Today we announced an expanded clinical dataset from the ongoing Phase 1b dose expansion clinical trial for ACTengine® IMA203 and updated Phase 1 dose escalation clinical data on our next-generation ACTengine® IMA203CD8 TCR-T cell therapy. In addition, we reported preclinical data on other next-generation T cell candidates and combination strategies. To read the full announcement, click here: https://lnkd.in/dHUurcEv #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews #SITC

🌏Last week, our employees gathered to celebrate Diwali, bringing the color and brightness of this festival into the office! 🪷Dressed in traditional attire, our team set the stage with vibrant decorations, traditional Indian snacks and festive activities like painting clay lamps called diyas and creating flower rangoli designs. Our talented coworkers even sang traditional Indian songs and danced to some lively Bollywood tunes, adding a fun and authentic touch to the festivities. 💫Thank you to everyone who helped make Diwali at Immatics a beautiful event filled with culture and creativity. #TeamBonding #Together #DiwaliCelebration #FestivalofLights #DiversityAndInclusion

🎉 Last week, the Cyber Valley Health Cluster hosted their official launch event in Tübingen, Germany to unite the forces of science, industry and start-ups. This initiative promotes joint projects between AI experts, scientists and companies to develop innovative solutions for current and future challenges in the healthcare sector. 🔬 Immatics is proud to be a part of the Cyber Valley Health community and facilitate the connection between science and industry in the region of Baden-Württemberg. 👉 Discover more about this exciting initiative and the launch event here: https://lnkd.in/eTiuyn_F #AI #Robotics #Health #HealthcareInnovation #MedicalTechnology #AIforGood #BetterTogether

📢 Starting on Wednesday, November 6th members of the Immatics team will be onsite at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In addition, don’t miss out on our upcoming oral and poster presentations at the conference. Get all the details on dates, times and titles here: https://lnkd.in/eaT7H3rb See you all there! #cancer #immunotherapy #SITC #immunooncology #immunology

Our Chief Medical Officer, Cedrik M. Britten, was recently interviewed for Charlotte Harrison’s article in Nature, “TCR cell therapies vanquish solid tumors — finally.” Read the article for more insights from experts in the dynamic field of TCR cell therapies for solid tumor cancers: https://lnkd.in/eUqcsRKU #solidtumors #cancer #oncology #celltherapy #biotech #immunotherapy

This year at Immatics, our staff motto is #MoveIt and that’s exactly what our team did at the 8th annual Hess Houston Corporate 5K! More than 50 of our colleagues came together to Memorial Park Conservancy to run/walk at Houston’s “Largest Office Party” to promote corporate wellness and team building. After crossing the finish line, our team celebrated at the Immatics tent with healthy snacks, refreshing drinks, live entertainment and more! It was a fun challenge and an excellent opportunity to demonstrate the determination we embody at Immatics in our daily mission of improving the lives of cancer patients. #HESS5K #GetFitHouston #TeamBuilding #EmployeeWellness #memorialpark #runhouston #CorporateWellness